Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

memo - Magazine of European Medical Oncology

Issue 2/2009

Content (15 Articles)

editorial

MEMO and paediatric oncology – Yes, we can!

Michael N. Dworzak

editorial

The Best is yet to come – New drugs in Haematology

W. Willenbacher

CECOG News

Initiation of the TURANDOT breast cancer study

Christoph Zielinski, Thomas Brodowicz

short review

Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy

Leo Kager

ASH report

Paediatric NEWS & NOTES from the 50th annual ASH meeting

Sabine K. Breuer

short review

New drugs in the treatment of acute myeloid leukaemia

S. Kayser, Richard F. Schlenk

short review

New approaches to the treatment of adult acute lymphoblastic leukaemia

Nicola Gökbuget, B. Wassmann

short review

Pathogenetic and clinical impact of JAK2 mutations in chronic myeloproliferative diseases

G. Webersinke, Holger Rumpold

short review

New treatment options for the management of non-Hodgkin lymphoma

S. Kassam, Silvia Montoto

ASH report – Lymphomas

The lymphomas: “Nothing New in the West”?

W. Willenbacher, E. Willenbacher

ASH report – CLL

Chronic lymphocytic leukaemia

Michael Steurer

ASH report – AML

Acute myeloid leukaemia (AML) and allogeneic haematopoietic stem cell transplantation

David Nachbaur

ASH report – MDS

Myelodysplastic syndromes (MDS)

Reinhard Stauder

San Antonio Report – breast cancer

News from endocrine treatment in breast cancer from the San Antonio Breast Cancer Symposium 2008

Brigitte Mlineritsch

case report

Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

W. L. Sun, G. Hutarew, J. Gradl, M. Gratzl, E. Heumader, H. Denz, Michael Fiegl

Apr 09
Issue: Special Issue 2/2009
Jun 09
Issue: Special Issue 4/2009

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits